Sample
Red Blood Cell Lysis and other biological samples
Intended Use
For quantitative detection of HbA1C in Red Blood Cell Lysis and other biological samples.
Performance Characteristics
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% within the expiration date under appropriate storage condition.
To minimize extra influence on performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is strongly suggested that the same operator performs the whole assay from the beginning to the end.
Precision
Intra-Assay: CV<8%
Inter-Assay: CV<10%
Detection Range
1.563-100ng/ml
Standard Curve
Results of a typical standard operation of a HbA1C ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)
Citations
Publication ()
Have you cited DEIABL-R1 in a publication?
Let us know and earn a reward for your research.
Neuroprotective Activity of Eriodictyol Against Streptozotocin-Induced Diabetic Peripheral Neuropathy in Wistar Rats by Targeting Wnt/β-Catenin Pathway
Malik R, Singh B, Kushwah AS, Kumar M
Applications: ELISA
Reactive species: Rats
"Abstract: Long-term hyperglycemia and insulin dysfunction deteriorate peripheral nerve functions, leading to sensory loss, spontaneous pain, and hypersensitivity (i.e., allodynia and hyperalgesia). Evidence indicates glucose-induced upregulation of the Wnt/β-catenin mechanism in diabetic peripheral neuropathy (DPN). Eriodictyol (Ed) has shown protective effects against glucotoxicity. The present study explored the bioactivity of Ed in streptozotocin (STZ) induced DPN and the role of the Wnt/β-catenin pathway. Ed or gabapentin (Gpn), or methyl vanillate (MV) was administered in Wistar rats for 4 weeks, starting 6 weeks after STZ administration. Ed ameliorated the mean body weight and mitigated polydipsia and polyphagia in DPN rats. The data indicated that Ed attenuated hyperglycemia, glycosylated hemoglobin (HbA1c) levels, and HOMA-IR, and enhanced circulating insulin levels and HOMA-β against STZ-induced DPN. MV (Wnt/β-catenin activator) caused a significant increase in STZ-induced hyperglycemia, HbA1c, HOMA-IR, and further decreased the insulin levels and HOMA-β in STZ-treated rats. Ed attenuated oxidative stress, inflammatory expression, level of advanced glycation end products, and nuclear factor kappa B in the sciatic nerve of STZ-treated neuropathic rats, and MV further potentiated these markers triggered by STZ. Interestingly, Ed and Gpn attenuated mRNA expression of Wnt1/β-catenin in the sciatic nerve of neuropathic rats. Hyperalgesia and allodynia were significantly ameliorated in Ed or Gpn-treated rats against DPN. Furthermore, Ed ameliorated the biochemical biomarkers, histopathological characteristics, and nociceptive-like responses in STZ and MV-treated rats. It is concluded that Ed can alleviate the pathogenic course of DPN. Wnt/β-catenin pathway might be involved in the eriodyctiol-triggered mitigation of nociceptive-like responses in diabetic rats."
Article snippet: Glycated hemoglobin (HbA1c) (ELISA kit CD Creative Diagnostics) levels were evaluated before treatment
(i.e., after 6 weeks of STZ injection) and after treatments (after 4 weeks of Ed treatment). 
Figure 1. Effects of Ed on plasma insulin, glycated hemoglobin (HbA1c), homeostatic model assessment (HOMA)-IR, and homeostatic model assessment (HOMA)-β in neuropathic rats.
Okanin alleviates symptoms of nociceptive-like responses in diabetic peripheral neuropathy in type 1 diabetic Wistar rats by regulating the AGEs/NF-κB/Nrf-2 pathway
Mohammad Rafiq Ganie, Nadeem Khan, Manish Shukla, Shreya Sood, Sushma Devi, Poonam Arora, Manish Kumar, Imtiyaz Ahmed Najar, Jianlei Tang
Applications: ELISA
Reactive species: Rat
"Abstract: Elevated reactive species and AGEs contribute to deregulation of transcription factors e.g., NF-κB and Nrf2 in diabetic peripheral neuropathy (DPN). Okanin, a bioactive chalcone, is active against redox imbalance, immune response, and pro-inflammatory events. The current investigation assessed effects of okanin in streptozotocin-induced DPN in rats. Wistar rats were divided into 6 groups (n = 6): Control, DPN, Okanin 2.5, Okanin 5, Okanin 10, and Gpn (Gabapentin). After 6 weeks of streptozotocin (55 mg/kg) injection, okanin (2.5, 5, 10 mg/kg), and gabapentin (50 mg/kg), were administered for 4 weeks. The streptozotocin-induced reduction in body weight, and increased feed/water intake, insulin, glucose, and HbA1c levels were mitigated by okanin or gabapentin. In DPN rats, Okanin or gabapentin ameliorated insulin resistance and β-cell function, inflammatory indices, and oxidative stress in the sciatic nerve of rodents thereby culminating in a decrease in hyperalgesia and allodynia. Okanin and streptozotocin-treated rats had significantly declined levels of AGEs, the receptor for AGEs, and NF-κB, and an upsurge in Nrf2 expression. In streptozotocin-induced DPN model, okanin ameliorates nociceptive-like responses by regulating the AGEs/NF-κB/Nrf2 pathway, suggesting that okanin has therapeutic value against DPN which needs further studies involving human subjects."
Article snippet: The circulating insulin (*), glycated hemoglobin (HbA1c) (DEIABL-R1 ELISA kit, CD Creative Diagnostics, NY, USA), homeostatic model assessment-insulin resistance, and homeostatic model assessment-β cell function were evaluated post-STZ exposure (i.e., before treatment) and after 4 weeks of okanin treatment (i.e., after 10 weeks). 
Figure 1. Okanin ameliorated plasma insulin, glycated hemoglobin (HbA1c), homeostatic model assessment (HOMA)-IR, and homeostatic model assessment (HOMA)-β in neuropathic rats
COA
Loading ......
